Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Progress of Drug Clinical Trial By a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
30 December 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Progress of Drug Clinical Trial By a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Chengdu Xingrui Jingxuan Therapeutics Company Limited* (成都星睿菁烜生物科技有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**"), initiated the Phase Ⅰ clinical trial of the theranostics radiopharmaceutical project SRT-007 in China (excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below). The trial is for the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

II. Research Progress of Investigational New Drugs

The theranostics radiopharmaceutical project SRT-007 includes two radiopharmaceutical injections: Gallium [68Ga] PSMA-0057 (diagnostic) and Lutetium [177Lu] PSMA-0057 (therapeutic). Gallium [68Ga] PSMA-0057 Injection is for diagnostic use, and Lutetium [177Lu] PSMA-0057 Injection is for therapeutic use.

As of November 2025, the Group (i.e., the Company and its subsidiaries/units) had invested approximately RMB 32.19 million (unaudited; including license fees) in total in the research and development (the "**R&D**") of SRT-007 at this stage.

As of the date of this announcement, NOVARTIS AG's Pluvicto is the only radiopharmaceutical drug with the same target approved worldwide. According to public information[1], Pluvicto generated sales of US$1.392 billion in 2024.

III. Risk Reminder

As required by applicable laws and regulations in China, the Gallium [68Ga] PSMA-0057 Injection and the Lutetium [177Lu] PSMA-0057 Injection must undergo a series of clinical studies and obtain approval from the relevant national drug regulatory authorities in China before they can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

30 December 2025

* For identification purpose only

[1] As disclosed in the 2024 Annual Report of NOVARTIS AG.